Q-Sera’s technology is based upon research emanating from the University of Queensland and is patent protected.
Family 1 Priority Date Sept 2010
This patent covers all prothrombin activators from snake venom including naturally occurring and recombinant versions in blood collection tubes for the production of serum for biochemical analysis.
May 2020: Patent granted or allowed in US, EU, Japan, China, Canada, Mexico, Russia, South Korea, South Africa and Australia.
Patent pending in India, Israel and Brazil.
Family 2 Priority Date Oct 2014
'Improved Clotting Composition'
Covers formulations to enhance the temperature and irradiation stability of snake venom prothrombin activators in blood collection tubes.
May 2020: Patent allowed in US and Japan.
Patent pending in EU, China, Canada, Australia and South Africa